Psychiatric symptom improvement from adjunctive statin prescribing in severe mental illness: three target trial emulation studies
Listed in
This article is not in any list yet, why not save it to one of your lists.Abstract
Background
Randomized controlled trials (RCTs) of statins as adjunct therapy for severe mental illness (SMI) have produced mixed results. Specific statin-antipsychotic combinations might improve psychiatric symptoms through: 1) blood-brain barrier (BBB) penetrant statins being anti-inflammatory/neuroprotective, and/or 2) statins that inhibit p-glycoprotein enhancing the effects of antipsychotics with high p-glycoprotein affinity.
Aim
To investigate these mechanisms via three target trial emulation studies.
Methods
We identified patients with SMI (schizophrenia, bipolar disorder, ‘other’ psychoses) prescribed antipsychotics/mood stabilisers and statins from 2000-2019 in English electronic health records. We defined three hypothetical RCTs and their observational analogues: 1) simvastatin (crosses BBB) vs. atorvastatin/pravastatin/rosuvastatin (non-penetrant); 2A) simvastatin/atorvastatin (p-glycoprotein inhibitors) vs. pravastatin in patients prescribed risperidone/olanzapine/aripiprazole (high p-glycoprotein affinity); 2B) risperidone/olanzapine/aripiprazole vs. quetiapine (low p-glycoprotein affinity) in patients prescribed simvastatin/atorvastatin. Primary outcome: 12-month psychiatric admissions. Secondary outcomes: self-harm, physical health, and accident/injury admissions.
Results
In 72,096 patients prescribed statins and antipsychotics/mood stabilisers, we found no reduction in psychiatric admissions at 12 months in patients prescribed: 1) BBB-penetrant vs. non-penetrant statins (HR:1.07; 95%CI:0.88-1.31); 2A) antipsychotics with p-glycoprotein affinity and p-glycoprotein inhibiting statins vs. statins without inhibition (HR:0.77; 95%CI:0.28-2.15); 2B) p-glycoprotein inhibiting statins with antipsychotics having p-glycoprotein affinity vs. antipsychotics without affinity (HR:0.93; 95%CI:0.79-1.09). In 2B we observed reduced self-harm (HR:0.60; 95%CI:0.38-0.97) in per-protocol analysis and reduced psychiatric admissions in the ‘other’ psychoses subgroup (HR:0.53; 95%CI:0.34-0.85).
Conclusions
BBB permeability is unlikely to be the mechanism by which statins improve SMI symptoms. Further research is needed to understand statin-antipsychotic interactions, and whether interaction with p-glycoprotein is a plausible mechanism.
